Navigation Links
TorreyPines Receives Notice of Delisting from Nasdaq Global Market
Date:7/20/2009

LA JOLLA, Calif., July 20 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) announced today that it had received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market notifying the Company that it did not comply with the minimum $10,000,000 stockholders' equity requirement for continued listing set forth in Listing Rule 5450(b)(1)(A), prior to the expiration of the extension granted by the Staff on July 14, 2009. TorreyPines initially received notification from the Staff of its noncompliance with the minimum $10,000,000 stockholders' equity requirement for continued listing on March 31, 2009.

The Company plans to request a hearing before the Nasdaq Listing Qualifications Panel to review the Staff determination to delist the Company's common stock. The request for a hearing will stay the Staff determination to delist the Company's common stock until the Panel renders a determination following the hearing. The hearing is expected to be scheduled within 30 to 45 days of the Company's request, which the Company will submit on July 21, 2009.

There can be no assurances that the Listing Qualifications Panel will grant the Company's request for continued listing on The Nasdaq Global Market, in which case the Company's common stock could be delisted from The Nasdaq Stock Market.

About TorreyPines Therapeutics, Inc.

TorreyPines Therapeutics, Inc. is a biopharmaceutical company which has been committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal has been to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine and
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. TorreyPines Therapeutics Announces its Board of Directors Approval of Plan of Liquidation and Dissolution
2. TorreyPines Therapeutics Reports First Quarter 2009 Financial Results
3. TorreyPines Therapeutics Receives Notice of Non-Compliance with Nasdaq Continued Listing Requirements
4. Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed
5. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2008 Results
6. First Multiple Dose Clinical Trial of TorreyPines Therapeutics Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
7. TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel
8. TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
9. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
10. TorreyPines Therapeutics Sells Alzheimers Disease Genetics Program to Eisai
11. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... 20, 2013 On 25-28 July, 2013, ... in Paris - the beautiful city of lights. , ... Medicine is revolutionizing the medical world. Understanding and integrating ... the hallmark of this transformation. Much of the present ... the epidemiologic studies of large cohorts that do not ...
(Date:5/20/2013)... Kitware, a leader in data visualization, ... the exploration of hospital costs across the United ... the recent release of “Medicare Provider Charge Data,” a ... procedures from the Centers for Medicare & Medicaid Services. ... at hospitals across the country has sparked considerable controversy; ...
(Date:5/20/2013)... May 20, 2013 In Early 2013, ... field of biotoxin related illnesses , announced his vision ... able to advance his protocol for treating Chronic Inflammatory ... the third physician to achieve certification in the Shoemaker ... able to practice the Shoemaker Protocol in other parts ...
(Date:5/20/2013)... City, CA (PRWEB) May 20, 2013 ... has announced the appointment of Lisa Baird as Executive ... on July 8, 2013. The WMIS vision ... imaging applications to understand and effectively treat diseases in ... Imaging Society (WMIS) was established in 2011 by integrating ...
Breaking Biology Technology:The International Congress on Personalized Medicine - Up Close and Personalized 2013 in Paris 2Kitware Enables Interactive Exploration of CMS Medicare Data 2Dr. Ritchie Shoemaker Certifies Third Physician in His Treatment Protocol for Chronic Inflammatory Response Syndrome (CIRS) 2WMIS Appoints Lisa Baird as Next Executive Director 2
... , COLUMBIA, Md., Sept. 2 ACell, ... Global Investment Conference. , , The conference ... the New York Palace Hotel in New York City. James DeFrancesco, ... presentation on September 11th beginning at 9:10 AM (EDT) in the ...
... , HAYWARD, Calif., Sept. 2 ... completed the second closing of its Series A equity financing ... round to $5.4 million. , , ACD ... proprietary diagnostic tests based on the company,s patent pending RNAscope(TM) ...
... , , , INDIANAPOLIS, ... company, today announced that, effective October 1, 2009, it would ... cents per kg for all non-contract customers or as existing ... continue to invest in expanding global supply for the high ...
Cached Biology Technology:ACell's CEO to Present at Rodman & Renshaw's 2009 Annual Global Investment Conference 2ACD Completes the Second Closing of Series A Financing and Initiates Services for Biomarker Validation and Companion Diagnostic Development 2
(Date:5/19/2013)... novel study reports that white men and women of ... (hallux valgus) and lesser toe deformities, including hammer or ... to estimate the heritability of foot disorders in humansappear ... published by Wiley on behalf of the American College ... as many as 60% of older adults have foot ...
(Date:5/19/2013)... a strain of electricity-producing bacteria that can grow using ... dioxide as its sole source of carbon. Researchers ... at the 113th General Meeting of the American Society ... current production solely on hydrogen," says Amit Kumar, a ... are part of the Lovley Lab Group at the ...
(Date:5/19/2013)... Scientists at the University of California, Davis have engineered ... need for light. They report their findings today ... for Microbiology. , "In this work, we used synthetic ... on carbon dioxide and light energy for growth) cyanobacterial ... says Jordan McEwen, the lead researcher on the study. ...
Breaking Biology News(10 mins):Blame your parents for bunion woes 2
... Capuchin monkeys are playful, inquisitive primates known for their ... New research now shows that just like humans, they ... the brain, specifically in the corpus callosum, the region ... A recently published paper by Associate Professor of Psychology ...
... hepatitis C virus (HCV). The outcome of HCV infections is ... chronic infections will develop into liver cirrhosis or liver cancer. ... is there any approved vaccine for this virus, hepatitis C ... fifty percent of HCV infected patients recovers spontaneously. The hepatitis ...
... test before taking the cancer drug irinotecan, and the ... guidelines to say so, according to researchers at the ... also known by its brand name Camptosar, is used ... FDA recommends screening patients for a gene that could ...
Cached Biology News:Influence of sex and handedness on brain is similar in capuchin monkeys and humans 2Who will recover spontaneously from hepatitis C virus infection 2UNC study questions FDA genetic-screening guidelines for cancer drug 2
Human alpha-1-antitrypsin. No cross-reactivity with alpha-1-acid glycoprotein, serum albumin or other serum proteins....
... to histochemically detect specific ... pH in cultured cells ... specific marker is only ... (not found in presenescent/quiescent/immortal ...
Recombinant Mouse LIGHT/TNFSF14...
Viral CMV UL146/vCXC1 Biotinylated Affinity Purified PAb...
Biology Products: